FDA Approves IV Therapy for Adults With Pulmonary Arterial Hypertension

Officials with the FDA have approved selexipag (Uptravi; Janssen) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class II–III, who are temporarily unable to take oral therapy.

Read more @ www.pharmacytimes.com